Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).

Franchimont, Denis;Ferrante, Marc;Louis, Edouard;De Vos, Martine;Vermeire, Séverine;et.al.
(2018) Acta Gastro-Enterologica Belgica — Vol. 81, n° 1, p. 49-53 (2018)

Files

2018_Franchimont_Acta_Gastroenterol_Belg.pdf
  • Open Access
  • Adobe PDF
  • 191.59 KB
Download

Details

Authors
Show more
Abstract
(en) Biosimilars are biological drugs which are similar to the authorized biologics (“reference product”) but not identical (1). The European legislation has offered since 2006 a legal framework for biosimilars. The concept and methodology of the comparative investigations are further treated in the guidelines of the European Medicines Agency (EMA) [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Franchimont, D., Ferrante, M., Louis, E., De Vos, M., Dewit, O., Van Hootegem, P., Moreels, T., Liefferinckx, C., Bossuyt, P., Baert, F., Rahier, J.-F., & Vermeire, S. (2018). Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). Acta Gastro-Enterologica Belgica, 81(1), 49-53. https://hdl.handle.net/2078.5/173521 (Original work published 2018)